ATE183084T1 - Behandlung des ermüdungssyndroms mit cholinesteraseinhibitoren - Google Patents

Behandlung des ermüdungssyndroms mit cholinesteraseinhibitoren

Info

Publication number
ATE183084T1
ATE183084T1 AT92910754T AT92910754T ATE183084T1 AT E183084 T1 ATE183084 T1 AT E183084T1 AT 92910754 T AT92910754 T AT 92910754T AT 92910754 T AT92910754 T AT 92910754T AT E183084 T1 ATE183084 T1 AT E183084T1
Authority
AT
Austria
Prior art keywords
cholinesterase
schizophrenia
treatment
benzodiazepines
anxiety
Prior art date
Application number
AT92910754T
Other languages
English (en)
Inventor
Ernir Snorrason
Original Assignee
Ernir Snorrason
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IS3706A external-priority patent/IS3706A7/is
Priority claimed from DK18192A external-priority patent/DK18192D0/da
Application filed by Ernir Snorrason filed Critical Ernir Snorrason
Application granted granted Critical
Publication of ATE183084T1 publication Critical patent/ATE183084T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Transceivers (AREA)
  • Mobile Radio Communication Systems (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT92910754T 1991-05-14 1992-05-14 Behandlung des ermüdungssyndroms mit cholinesteraseinhibitoren ATE183084T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IS3706A IS3706A7 (is) 1991-05-14 1991-05-14 Notkun á galantamine-hydróbrómíði í geðlæknisfræði
DK18192A DK18192D0 (da) 1992-02-13 1992-02-13 Method of treating chronic fatigue syndrome

Publications (1)

Publication Number Publication Date
ATE183084T1 true ATE183084T1 (de) 1999-08-15

Family

ID=36886660

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92910754T ATE183084T1 (de) 1991-05-14 1992-05-14 Behandlung des ermüdungssyndroms mit cholinesteraseinhibitoren

Country Status (13)

Country Link
US (1) US5312817A (de)
EP (2) EP0584185B1 (de)
JP (1) JP3291730B2 (de)
AT (1) ATE183084T1 (de)
CA (1) CA2108880A1 (de)
DE (1) DE69229781T2 (de)
DK (1) DK0584185T3 (de)
ES (1) ES2134215T3 (de)
GR (1) GR3031559T3 (de)
IE (1) IE921547A1 (de)
NO (1) NO307078B1 (de)
NZ (1) NZ242744A (de)
WO (1) WO1992020327A1 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2174851T3 (es) * 1992-07-24 2002-11-16 Univ California Farmacos que aumentan las respuestas sinapticas mediadas por receptores ampa.
DE4301782C1 (de) * 1993-01-23 1994-08-25 Lohmann Therapie Syst Lts Verwendung von Galanthamin zur Behandlung der Nicotinabhängigkeit
DE4301783C1 (de) * 1993-01-23 1994-02-03 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Galanthamin als wirksamem Bestandteil
US6323196B1 (en) * 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
US6316439B1 (en) * 1993-10-15 2001-11-13 Aventis Pharamaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
US6323195B1 (en) * 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
US5585375A (en) * 1994-07-01 1996-12-17 Davis; Bonnie M. Method for alleviating jet lag
DE19509663A1 (de) * 1995-03-17 1996-09-19 Lohmann Therapie Syst Lts Verfahren zur Isolierung von Galanthamin
DE19533772C1 (de) * 1995-09-12 1998-01-02 Hexal Ag Tacrin/Selegilin-Pflaster
SE9504537D0 (sv) * 1995-12-19 1995-12-19 Jan Hedner Sätt att behandla och diagnosticera andningsstörningar under sömn och medel för utförande av sättet
GB9606736D0 (en) 1996-02-19 1996-06-05 Shire International Licensing Therapeutic method
US5712259A (en) * 1996-04-22 1998-01-27 Birkmayer Pharmaceuticals NADH and NADPH pharmaceuticals for treating chronic fatigue syndrome
TW506836B (en) * 1996-06-14 2002-10-21 Janssen Pharmaceutica Nv Fast-dissolving galanthamine hydrobromide tablet
US6537997B1 (en) 1997-02-18 2003-03-25 A. Martin Lerner Method for diagnosing and alleviating the symptoms of chronic fatigue syndrome
US5872123A (en) * 1997-02-18 1999-02-16 Lerner; A. Martin Method for diagnosing and alleviating the symptoms of chronic fatigue syndrome
US6399622B1 (en) 1997-02-18 2002-06-04 A. Martin Lerner Method for diagnosing and alleviating the symptoms of chronic fatigue syndrome
EP1891954A3 (de) 1998-09-30 2009-01-14 Takeda Pharmaceutical Company Limited Wirkstoffe zur Verbesserung der Exkretionskraft der Harnblase
US20020177593A1 (en) 1998-09-30 2002-11-28 Yuji Ishihara Agents and crystals for improving excretory potency of urinary bladder
CA2345767A1 (en) * 1998-10-16 2000-04-27 Paul Leonce Irma De Nijs Therapy for improving cognition
OA11740A (en) 1998-12-24 2005-05-13 Janssen Pharmaceutica Nv Controlled release galantamine composition.
US8603546B2 (en) * 1999-01-11 2013-12-10 Herbaceuticals Inc. Herbal supplement for increased muscle strength and endurance for athletes
EP1150695B1 (de) * 1999-01-11 2007-02-28 Atanas Russinov Djananov Nahrungszusatz aus kräutern zur steigerung der muskulären kraft und ausdauer von athleten
MXPA02005667A (es) 1999-12-10 2004-09-10 Bonnie Davis Analogos de galantamina y licoramina como moduladores de los receptores nicotinicos.
CA2310950C (en) * 2000-04-03 2005-11-08 Janssen Pharmaceutica N.V. An efficacious dosage regiment of galantamine that reduces side effects
US6825177B2 (en) * 2000-10-30 2004-11-30 Parker Hughes Institute Aryl phosphate derivatives of d4T with potent anti-viral activity
AU2004216360B2 (en) * 2003-02-27 2009-09-17 Eisai R & D Management Co., Ltd. Pharmaceutical composition for treatment of drug dependence
WO2005016327A2 (en) * 2003-08-13 2005-02-24 Janssen Pharmaceutica, N.V. Treatment of sleep disorders with cholinesterase inhibitors
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
DE10354894A1 (de) * 2003-11-24 2005-07-07 Hf Arzneimittelforschung Gmbh Orale Formulierungen des Desoxypeganins und deren Anwendungen
WO2006040688A2 (en) 2004-10-12 2006-04-20 Ernir Snorrason Inhibitors of acetylcholinesterase for treating skin diseases
EP1777222A1 (de) 2005-09-22 2007-04-25 Galantos Pharma GmbH Cholinesterase Inhibitoren mit erhöter Blut Hirn Schranke Permeabilität zur Behandlung von kognitiven Störungen
US20090253654A1 (en) 2005-09-22 2009-10-08 Galantos Pharma Gmbh Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
US7803778B2 (en) 2006-05-23 2010-09-28 Theracos, Inc. Glucose transport inhibitors and methods of use
US8748419B2 (en) 2006-06-16 2014-06-10 Theracos, Inc. Treating obesity with muscarinic receptor M1 antagonists
US7893053B2 (en) 2006-06-16 2011-02-22 Theracos, Inc. Treating psychological conditions using muscarinic receptor M1 antagonists
CN101652377A (zh) 2007-04-02 2010-02-17 泰拉科斯有限公司 苄基化糖苷衍生物及其用法
US7838499B2 (en) 2007-08-23 2010-11-23 Theracos, Inc. Benzylbenzene derivatives and methods of use
CN102149280B (zh) 2008-07-15 2017-05-24 泰拉科斯有限公司 氘化苄基苯衍生物及其使用方法
ME02702B (de) 2008-08-22 2017-10-20 Theracos Sub Llc Verfahren zur herstellung von sglt2-hemmern
CN102264743B (zh) 2008-11-25 2015-02-11 罗彻斯特大学 Mlk抑制剂及其使用方法
WO2010123184A1 (ko) * 2009-04-24 2010-10-28 제주대학교 산학협력단 노르갈란타민 화합물을 유효성분으로 함유하는 탈모 질환의 예방 및 치료용 조성물
ES2332645B1 (es) * 2009-06-30 2010-10-18 Grifols, S.A. Utilizacion de alfa-1-antitripsina para la preparacion de medicamentos para el tratamiento del sindrome de fatiga cronica.
NZ603644A (en) 2010-05-24 2014-10-31 Univ Rochester Bicyclic heteroaryl kinase inhibitors and methods of use
WO2011153712A1 (en) 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
WO2012112933A1 (en) 2011-02-18 2012-08-23 The Scripps Research Institute Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
US8524664B2 (en) 2011-06-02 2013-09-03 Colorado Seminary, Which owns and Operates The Univeristy of Denver Methods of treating overproduction of cortisol using ACTH antagonist peptides
US20140100238A1 (en) 2012-10-04 2014-04-10 Ohio State University Method of diagnosing and treating epstein barr virus-based myalgic encephalomyelitis chronic fatigue syndrome patients
EP2925319B1 (de) 2012-11-30 2019-01-09 University Of Rochester Mixed-lineage-kinaseinhibitoren für hiv/aids-therapien

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3221827A1 (de) * 1982-06-09 1983-12-15 DSO Pharmachim, Sofija Biostimulierendes mittel
US4663318A (en) * 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
KR100195399B1 (ko) * 1987-05-04 1999-06-15 보니데이비스 알쯔하이머 병 치료용 의약

Also Published As

Publication number Publication date
EP0515301A2 (de) 1992-11-25
NO934104L (no) 1993-11-12
DE69229781D1 (de) 1999-09-16
NO934104D0 (no) 1993-11-12
GR3031559T3 (en) 2000-01-31
AU658424B2 (en) 1995-04-13
AU1886392A (en) 1992-12-30
NZ242744A (en) 1997-02-24
NO307078B1 (no) 2000-02-07
DE69229781T2 (de) 2000-01-05
ES2134215T3 (es) 1999-10-01
CA2108880A1 (en) 1992-11-15
EP0584185B1 (de) 1999-08-11
EP0584185A1 (de) 1994-03-02
WO1992020327A1 (en) 1992-11-26
EP0515301A3 (en) 1993-06-16
US5312817A (en) 1994-05-17
JPH06507617A (ja) 1994-09-01
IE921547A1 (en) 1992-11-18
DK0584185T3 (da) 2000-02-07
JP3291730B2 (ja) 2002-06-10

Similar Documents

Publication Publication Date Title
ATE183084T1 (de) Behandlung des ermüdungssyndroms mit cholinesteraseinhibitoren
ATE178791T1 (de) Behandlung von schizophrenie mit hilfe von cholinesteraseinhibitoren
ATE412415T1 (de) Inhibitoren der phosphodiesterase der zyklischen nucleotiden, mit einer benzodiazepinischen struktur, und deren verwendung in therapie
AR008853A1 (es) Nuevos compuestos farmaceuticamente activos, su uso en la fabricacion de medicamentos, metodo de tratamiento, composicion farmaceutica, compuestosintermediarios y proceso para la fabricacion de dichos compuestos
GB9921150D0 (en) Therapeutic agents
MX9600832A (es) Uso de pirazolopirimidinas y pirrolopirimidinas para la preparacion de composiciones para el tratamiento de trastornos neuronales y otros trastornos.
AR016453A1 (es) Pirazolopirimidinas y perazolotriazinas, un procedimiento para su preparacion, medicamentos y el uso de las mismas para la elaboracion de los medicamentos
DE60232029D1 (de) N-ä1h-indol-5-ylünaphthalin-1-sulphonamid-derivate und verwandte verbindungen als serotonin 5-ht6 rezeptor antagonisten zur behandlung von erkrankungen des zentralen nervensystems
SE9702564D0 (sv) New compounds
SE9702563D0 (sv) Compounds
Grahame et al. Alcohol place preference conditioning in high-and low-alcohol preferring selected lines of mice
BR0210222A (pt) Derivado de benzoxazepina, composição farmacêutica, uso de um derivado de benzoxazepina, e, método para tratar uma doença neurológica ou distúrbio psiquiátrico
DE69824195D1 (de) Dipyridoimidazolderivate zur behandlung von störungen des zentralen nervensystems
AR024963A1 (es) Oxazincarbazoles en el tratamiento de enfermedades del snc
NO20021041L (no) Polymorfismer av N-metyl-N-(3{3-[2-tienylkarbonyl]pyrazol- [1,5-alfa]-pyrimidin-7-yl}fenyl)acetamid og blandinger ogfremgangsmåter relatert dertil
ATE159018T1 (de) Pyrrolo(2,3-d>azepinderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
Houlihan et al. Sleep-inducing N-alkyl-5-[m-(trifluoromethyl) phenyl]-5-hydroxy-2-pyrrolidinones and N-alkyl-3-(trifluoromethyl) cinnamamides
ATE112256T1 (de) 9-amino-2-phenylbicyclo(3.3.1>nonane und 9-amino- 2-phenylbicyclo(3.3.1>-non-2-ene und diese enthaltende therapeutische mittel.

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee